GSK's Q2 2025 results reflect strong financial performance driven by Specialty Medicines and vaccines, significant R&D progress, and robust cash generation. However, challenges remain in the form of supply chain costs, market difficulties in China, and delayed product launches.

Company Guidance -

Q3 2025

In the recent GSK Q2 2025 Results Call, the company reported robust financial performance and progress in R&D, emphasizing the growth across its portfolio. Group sales increased by 6%, driven by a 15% rise in Specialty Medicines and a 9% uptick in vaccine sales. Core operating profit and core earnings per share saw significant growth, rising by 12% and 15% respectively. The company generated GBP 3.7 billion in cash during the first half, supporting investments and shareholder returns, including a dividend of 16p and GBP 800 million in share buybacks. GSK announced it expects to reach the top end of its financial guidance for 2025, highlighting the Specialty Medicines as a key growth driver, projected to account for over 50% of sales by 2031. The R&D pipeline is also progressing well, with three FDA approvals achieved this year and several pivotal trials set to begin. The company reiterated its commitment to responsible business practices, including expanding its voluntary licensing agreement for HIV treatment.

Strong Financial Performance

Group sales increased by 6%, core operating profit rose by 12%, and core earnings per share grew by 15% to 46.5p. Specialty Medicines sales were up 15%, and vaccine sales increased by 9%.

R&D Progress and FDA Approvals

Three FDA approvals were achieved this year, and the company is on track for two more. GSK expects pivotal trial readouts for six scale opportunities over the next 18 months.

Positive Cash Generation

Cash generation remains strong with GBP 3.7 billion generated in the first half. The company completed more than GBP 800 million of the share buyback program.

Updated Financial Guidance

GSK expects to deliver towards the top end of their financial guidance for 2025, indicating strong financial confidence and performance momentum.

HIV Portfolio Growth

The HIV portfolio delivered exceptional growth of 12% in the quarter, with long-acting injectables and Dovato driving demand.

GlaxoSmithKline (GSK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GSK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	1.24 / -	1.293	―	―	―
Jul 30, 2025	2025 (Q2)	1.17 / 1.24	1.115	10.85% (+0.12)
Apr 30, 2025	2025 (Q1)	1.04 / 1.20	1.077	11.33% (+0.12)
Feb 05, 2025	2024 (Q4)	0.49 / 0.58	0.736	-21.06% (-0.16)
Oct 30, 2024	2024 (Q3)	1.15 / 1.29	1.222	5.81% (+0.07)
Jul 31, 2024	2024 (Q2)	0.98 / 1.11	1.003	11.17% (+0.11)
May 01, 2024	2024 (Q1)	0.92 / 1.08	0.923	16.68% (+0.15)
Jan 31, 2024	2023 (Q4)	0.74 / 0.74	0.636	15.72% (+0.10)
Nov 01, 2023	2023 (Q3)	1.11 / 1.22	1.075	13.67% (+0.15)
Jul 26, 2023	2023 (Q2)	0.89 / 1.00	0.835	20.12% (+0.17)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GSK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$37.67	$38.97	+3.45%
Apr 30, 2025	$38.53	$39.40	+2.26%
Feb 05, 2025	$34.08	$36.87	+8.19%
Oct 30, 2024	$36.93	$35.81	-3.03%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.